Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMarechale Cap. Regulatory News (MAC)

Share Price Information for Marechale Cap. (MAC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.50
Bid: 1.40
Ask: 1.60
Change: 0.00 (0.00%)
Spread: 0.20 (14.286%)
Open: 1.50
High: 1.50
Low: 1.50
Prev. Close: 1.50
MAC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half Yearly Report

17 Dec 2015 07:00

RNS Number : 3395J
Marechale Capital PLC
17 December 2015
 

17 December 2015

 

Marechale Capital plc

("Marechale" or the "Company")

 

Interim Results

Marechale Capital plc today announces its unaudited interim results for the six months ended 30 September 2015.

Chairman's Statement

Marechale's gross profit of £192,000 (2014 £228,000) is lower than the comparable period last year and, as a result, I report that the Company has made a loss before tax of £48,000 (2014 £46,000 loss) during the first half of the year. On the other hand, I am pleased to report that overheads have been reduced by almost 10% from £277,000 (2014) to £251,000.

Marechale's usual business cycle has traditionally resulted in the bulk of its revenues being generated in the second half of the financial year, and it appears at this stage that this will be the case in the current year.

During the first half Marechale has been appointed to raise growth and development capital for a series of client transactions, and whilst the Company has had a good deal flow, a number of its deals have taken, or are taking, longer to complete; all completed transactions are detailed on the Company's website at www.marechalecapital.com.

Marechale operates as a corporate finance advisory and capital fund raising business focusing on growth companies in two primary sectors in which the team have a long term track record; Leisure and Retail, and Renewable Energy.

Marechale helps management teams to finance or refinance in two key areas of activity; Growth Capital (private equity transactions for more established businesses) and Development Capital (fundraising for smaller growth companies), the latter typically being Enterprise Investment Scheme (EIS) qualifying.

Marechale's joint venture renewable energy company, Northfield UK Solar Limited ("Northfield"), established in July 2013, is developing a portfolio of solar sites. Northfield continues to have a challenging time as its first large scale solar project, whilst achieving the necessary Grid connection offer, was turned down in Planning, and the subsequent appeal has also failed, as announced on 6th November.

Northfield's second scheme has achieved Planning permission and has an agreed Grid connection offer. The project was supposed to be bid into the 2015 CfD auction, although it has recently been announced that there will be no solar subsidies in this year's auction. Solar has not been ruled out of other future auctions, and, because the scheme is not able to connect to the Grid until Q3/Q4 2017, there is a possibility that the site will receive the CfD. Also, whilst subsidy payments make a huge difference to the likely returns that this and Northfield's other projects, that are currently on hold, could achieve, there is potential value without them. Northfield is actively considering a number of other commercial opportunities, such as combining schemes with other renewable technologies that complement the solar projects and share in the costs, or selling to an EPC owner/operator who is looking to operate solar pv schemes without government support. Any such value would enhance Northfield's value, which would benefit Marechale and its shareholders as a result. We have again adjusted the value of Marechale's shareholding in Northfield on the Company's balance sheet to £146,000, to reflect the opportunity value and likely risks to this being achieved.

In addition, Marechale continues to work closely with its other renewable energy clients, and particularly with its anaerobic digestion EIS fund, which has recently installed and commissioned a 2MW AD plant in Norfolk. Marechale's client, Future Biogas Ltd, has now built or has in development a total of ten such plants in the UK, and is the UK's leading AD business.

In the Leisure and Retail sector, the Company has successfully completed a number of deals including raising additional EIS funding for Brewhouse & Kitchen, and acquiring a hotel in Majorca on behalf of one of its investor syndicates.

Marechale is a specialist adviser and funder to growth companies in the Leisure and Retail sector, and has successfully launched the Odexia Consumer Brand Fund, which invests in EIS qualifying food, drink and cosmetic growth brands. The first funding round has been completed and it hopes shortly to be able to announce its first investment in an exciting new ice cream brand.

We are taking steps to increase the Company's resources, and expect to announce a senior staff appointment in January 2016.

The Directors believe that backing the right growth companies, whilst not without its risks, represents an interesting private equity investment class for investors looking to diversify their portfolios; over the last five years investors in all Marechale's transactions would have achieved an IRR of over 20% per annum.

We will announce our full year's results in the summer of 2016.

 

Mark Warde-Norbury

Chairman

17 December 2015

 

 

 

For further information please contact:

 

Marechale Capital

Mark Warde-Norbury / Patrick Booth-Clibborn

 

Tel: +44 (0)20 7628 5582

Smith & Williamson Corporate Finance

Azhic Basirov / David Jones

 

Tel: +44 (0)20 7131 4000

 

 

Consolidated Income Statement (unaudited)

Six months ended 30 September 2015

30 Sept

30 Sept

2015

2014

£

£

Revenue

297,275

244,500

Cost of sales

(105,493)

(16,464)

Gross profit

191,782

228,036

Administrative expenses

(251,041)

(276,978)

Operating profit/ (loss)

(59,259)

(48,942)

Investment revenues

-

-

Other gains

5,005

2,999

Exceptional gain on dilution of interest in associate

5,726

135,759

Net (loss) in respect of associate

630

(21,607)

Provision for project loss in associate

-

(114,000)

(Loss) before tax

(47,898)

(45,791)

Taxation

-

(152)

(Loss) for the period

(47,898)

(45,943)

(Loss) per share

(Pence)

(Pence)

- Basic

(0.08)

(0.08)

- Diluted

(0.08)

(0.08)

 

 

 

 

Consolidated Balance Sheet (unaudited)

As at 30 September 2015

30 Sept

30 Sept

2015

2014

£

£

Non current assets

Investment in associate

146,150

119,845

Current assets

Available for sale investments

150,917

113,921

Trading investments

128,254

77,125

Trade and other receivables

210,226

89,226

Cash and cash equivalents

359,346

264,355

848,743

544,627

Total assets

994,893

664,472

Current liabilities

Trade and other payables

(193,696)

(57,568)

Total current liabilities

(193,696)

(57,568)

Net assets

801,196

606,904

Equity

Capital and reserves attributable to equity shareholders

Share capital

2,474,308

2,474,308

Share premium account

1,247,379

1,247,379

Revaluation reserve

88,885

51,889

Reserve for own shares

(50,254)

(50,254)

Retained losses

(2,968,196)

(3,116,418)

Reserve for share based payments

9,075

-

801,196

606,904

 

 

Consolidated Cash Flow Statement

Six months ended 30 September 2015

30 Sept

30 Sept

2015

2014

£

£

Net cash from operating activities

Operating (loss)

(59,259)

(48,942)

Provision for share based payments

-

-

Operating cash flows before movements in working capital

(59,259)

(48,942)

Movement in working capital

Decrease in receivables

280,882

131,777

(Decrease) in payables

(162,347)

(91,750)

118,536

40,027

Operating cash flow

59,277

(8,915)

Investment activities

Interest receivable

-

-

Proceeds on disposal of trading investments

5,005

-

Proceeds on disposal of available for sale investments

-

2,999

Expenditure on available for sale investments

-

(4,997)

Cash flow from investing activities

64,282

(10,913)

Financing

Issue of share capital

-

-

Interest payable

-

-

Cash flow from financing activities

-

-

Net increase/(decrease) in cash and cash equivalents

64,282

(10,913)

Cash and cash equivalents at start of the period

295,064

275,268

Cash and cash equivalents at end of the period

359,346

264,355

Increase/(Decrease) in cash and cash equivalents

64,282

(10,913)

 

This financial information has been prepared in accordance with IFRS and International Financial Reporting Interpretations Committee ('IFRIC') interpretations adopted by the European Union, and with those parts of the Companies Act 2006 applicable to companies reporting under IFRS, with the prior period being reported on the same basis.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR KQLFFELFEFBD
Date   Source Headline
29th Sep 20103:06 pmRNSResult of AGM
22nd Sep 201010:34 amRNSDirector/PDMR Shareholding
7th Sep 201012:00 pmRNSFinal Results and Notice of General Meeting
17th Mar 20109:00 amRNSChange of Adviser
22nd Feb 20103:15 pmRNSResult of GM
12th Feb 201012:00 pmRNSDirector/PDMR Shareholding
4th Feb 201011:00 amRNSDirector/PDMR Shareholding
29th Jan 201012:00 pmRNSNotice of General Meeting
12th Jan 20107:00 amRNSApplication for New Ordinary Shares
23rd Dec 20092:31 pmRNSHalf Yearly Report
17th Dec 20095:15 pmRNSResult of AGM
7th Dec 200912:28 pmRNSHoldings in Company / Directors Dealings
23rd Nov 20097:00 amRNSAcquisition and AGM
23rd Oct 20099:17 amRNSHolding in Company
15th Oct 20092:41 pmRNSChange of Name of Nominated Adviser and Broker
30th Sep 20094:00 pmRNSAnnual Report & Accounts
18th Sep 20097:00 amRNSNotifiable Interests
18th Sep 20097:00 amRNSHolding in Company
28th Aug 20092:30 pmRNSAcquisition of Whim Gully Capital LLP
28th Aug 20092:30 pmRNSPreliminary Results and Notice of General Meeting
21st Jul 20097:00 amRNSDisposal
6th Aug 200810:59 amRNSDirector/PDMR Shareholding
23rd Jun 20087:00 amRNSAppointment of joint broker

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.